Skip to content
2000
Volume 12, Issue 11
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Matrix metalloproteinases (MMPs) have been implicated in both normal and pathologic processes. In cancer in particular, in vitro and animal studies showed an involvement of MMPs in many stages of cancer progression. This led to the development of MMP inhibitors that in most cases failed in clinical trials. In this review we go over the role of MMPs in the different stages of cancer progression and try to understand why the early generation of MMP inhibitors failed. The analysis of the lessons from this first experience, plus the review of the current knowledge that shows that MMPs may be pro-or anti-tumorigenic may set the stage for a future success for this therapeutic strategy in cancer.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/138920111798377085
2011-11-01
2025-06-22
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/138920111798377085
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test